- Home
- INO vs IVVD Comparison
INO vs IVVD Comparison
Compare INO & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- IVVD
- Stock Information
- Founded
- INO 1979
- IVVD 2020
- Country
- INO United States
- IVVD United States
- Employees
- INO N/A
- IVVD N/A
- Industry
- INO Medical/Dental Instruments
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- INO Health Care
- IVVD Health Care
- Exchange
- INO Nasdaq
- IVVD Nasdaq
- Market Cap
- INO 110.7M
- IVVD 116.8M
- IPO Year
- INO 1998
- IVVD 2021
- Fundamental
- Price
- INO $1.96
- IVVD $0.49
- Analyst Decision
- INO Buy
- IVVD Strong Buy
- Analyst Count
- INO 6
- IVVD 5
- Target Price
- INO $16.33
- IVVD $7.11
- AVG Volume (30 Days)
- INO 1.2M
- IVVD 859.7K
- Earning Date
- INO 11-14-2024
- IVVD 11-14-2024
- Dividend Yield
- INO N/A
- IVVD N/A
- EPS Growth
- INO N/A
- IVVD N/A
- EPS
- INO N/A
- IVVD N/A
- Revenue
- INO $203,413.00
- IVVD $11,564,000.00
- Revenue This Year
- INO N/A
- IVVD N/A
- Revenue Next Year
- INO $2,290.97
- IVVD $486.65
- P/E Ratio
- INO N/A
- IVVD N/A
- Revenue Growth
- INO N/A
- IVVD N/A
- 52 Week Low
- INO $1.91
- IVVD $0.45
- 52 Week High
- INO $14.75
- IVVD $5.20
- Technical
- Relative Strength Index (RSI)
- INO 12.76
- IVVD 30.99
- Support Level
- INO $3.96
- IVVD $0.57
- Resistance Level
- INO $4.08
- IVVD $0.62
- Average True Range (ATR)
- INO 0.25
- IVVD 0.07
- MACD
- INO -0.19
- IVVD -0.01
- Stochastic Oscillator
- INO 1.85
- IVVD 12.05
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.